Middle East, North Africa, Afghanistan & Pakistan (excluding high income) vs Tajikistan: Access to anti-retroviral drugs, female

Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
38.4%
in 2024
Tajikistan
95.0%
in 2024
Middle East, North Africa, Afghanistan & Pakistan (excluding high income) rank
18th
Tajikistan rank
19th

Access to anti-retroviral drugs, female over time

  • Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
  • Tajikistan
020406080100200020122024

How they compare

Tajikistan currently reports 95.0% against 38.4% in Middle East, North Africa, Afghanistan & Pakistan (excluding high income), a difference of 56.6%.

That makes Tajikistan's figure about 2.5 times Middle East, North Africa, Afghanistan & Pakistan (excluding high income)'s.

The two have swapped places 1 time across 25 shared years of data; in 2000 it was Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ahead.

Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ranks 18th and Tajikistan ranks 19th of 19 groups.

Across the 3 decades both report, Middle East, North Africa, Afghanistan & Pakistan (excluding high income) averaged higher in 1 and Tajikistan in 2.

Head to head by decade

Decade Middle East, North Africa, Afghanistan & Pakistan (excluding high income) Tajikistan Difference Ahead
2000s 3.8% 0.7% 3.1% Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
2010s 20.3% 29.8% 9.5% Tajikistan
2020s 34.3% 83.4% 49.1% Tajikistan

Averages of every year both report within each decade.

Frequently asked questions

Which has higher access to anti-retroviral drugs, female, Middle East, North Africa, Afghanistan & Pakistan (excluding high income) or Tajikistan?
Tajikistan, at 95.0% against 38.4% in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) as of 2024.
What is the difference in access to anti-retroviral drugs, female between Middle East, North Africa, Afghanistan & Pakistan (excluding high income) and Tajikistan?
56.6%, with Tajikistan ahead.
How many years of comparable data are there for Middle East, North Africa, Afghanistan & Pakistan (excluding high income) and Tajikistan?
25 years are reported by both, from 2000 to 2024.
How do Middle East, North Africa, Afghanistan & Pakistan (excluding high income) and Tajikistan rank globally for access to anti-retroviral drugs, female?
Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ranks 18th and Tajikistan ranks 19th of 19 groups.
Where does this data come from?
UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

Share, cite or embed this page

Cite this page

Middle East, North Africa, Afghanistan & Pakistan (excluding high income) vs Tajikistan: Access to anti-retroviral drugs, female. Statizoid, drawing on UNAIDS estimates. Retrieved 18 September 2026, from https://gender.statizoid.com/compare/access-to-anti-retroviral-drugs-female-percent/middle-east-north-africa-afghanistan-and-pakistan-excluding-high-income/tajikistan/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/compare/access-to-anti-retroviral-drugs-female-percent/middle-east-north-africa-afghanistan-and-pakistan-excluding-high-income/tajikistan/">Middle East, North Africa, Afghanistan & Pakistan (excluding high income) vs Tajikistan: Access to anti-retroviral drugs, female</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.